TG Therapeutics Inc

8 paź 2026, 19:15 UTC

TG Therapeutics schedules the 10th Joint ACTRIMS-ECTRIMS Meeting for October 21-23, 2026, to present initial clinical results of Azer-Cel and BRIUMVI data.

7 paź 2026, 20:01 UTC

TG Therapeutics Inc is trading higher, having previously peaked earlier in the session before pulling back, and remains below its 20-day moving average.

6 paź 2026, 20:00 UTC

TG Therapeutics Inc shares fell sharply, reaching an early high before declining significantly, remaining well below its 20-day moving average.

5 paź 2026, 20:06 UTC

TG Therapeutics Inc. shares fell sharply, pulling back from Friday's close after earlier reaching a session high, amid multiple year-end catalysts.

2 paź 2026, 19:26 UTC

TG Therapeutics is trading higher amid social media buzz over a buy recommendation and an $86 price target for its anti-CD20 treatment, Briumvi.

1 paź 2026, 23:05 UTC

TG Therapeutics Inc is trading modestly higher in after-market hours, despite remaining below its 20-day moving average after three consecutive sessions finishing lower.

30 wrz 2026, 20:07 UTC

TG Therapeutics Inc shares fell modestly following Tuesday's close, amid a broader market decline, and are currently near the midpoint of their one-month trading range.

28 wrz 2026, 20:07 UTC

TG Therapeutics Inc shares are declining, continuing a downward trend since Friday's close amid a broader market downturn, despite a brief recovery attempt.

25 wrz 2026, 21:01 UTC

TG Therapeutics Inc declined in after-market trading, reversing an initial uptick and moving lower from Friday's close, despite remaining above its 20-day moving average.

24 wrz 2026, 23:45 UTC

TG Therapeutics Inc declined in after-market hours on Thursday, moving from a larger drop to a more modest decrease while remaining above its 20-day moving average.

23 wrz 2026, 23:01 UTC

TG Therapeutics Inc declined in after-market trading, reversing an initial uptick, despite strong U.S. economic data indicating robust growth in the private sector.

22 wrz 2026, 22:06 UTC

TG Therapeutics Inc saw a slight decline in after-market trading, despite recent strength, as economic data showed a contraction in manufacturing activity.

21 wrz 2026, 19:16 UTC

TG Therapeutics shares are advancing as discussions highlight BRIUMVI's growing momentum and market share gains in the IV anti-CD20 market for relapsing multiple sclerosis.

18 wrz 2026, 20:06 UTC

TG Therapeutics is trading modestly higher, rebounding after an earlier pullback, and has now finished higher for three consecutive sessions.

17 wrz 2026, 19:54 UTC

TG Therapeutics Inc is moving higher as economic data shows unexpected labor market strength, despite a decline in housing starts.

16 wrz 2026, 23:56 UTC

TG Therapeutics Inc is trading lower in after-market hours, retracing from an initial high shortly after the market closed, despite remaining above its 20-day moving average.

15 wrz 2026, 23:41 UTC

TG Therapeutics shares are lower in after-market trading amid negative market sentiment. The New York Empire State Manufacturing Index fell sharply, raising investor caution.

14 wrz 2026, 19:16 UTC

TG Therapeutics Inc shares are lower today amid broader market declines. CEO Weiss highlighted upcoming catalysts, including a significant treatment administration method.

11 wrz 2026, 20:08 UTC

TG Therapeutics shares are declining during Friday's session, despite social media optimism about its subcutaneous BRIUMVI formulation and potential Priority Review Voucher benefits.

10 wrz 2026, 20:31 UTC

TG Therapeutics Inc shares are lower in after-market trading, reflecting a decline despite starting the session near the top of their one-month range.

9 wrz 2026, 20:07 UTC

TG Therapeutics shares are lower today amid cautious outlook from CEO Weiss and mixed analyst sentiment on sales estimates. Earlier, the stock pulled back from session highs.

4 wrz 2026, 20:07 UTC

TG Therapeutics Inc is declining amid increased selling pressure in risk assets following a strong jobs report raising monetary policy concerns.

3 wrz 2026, 20:07 UTC

TG Therapeutics will participate in the Cantor Global Healthcare Conference. Shares are lower today, despite earlier gains and positive sentiment surrounding the company.

2 wrz 2026, 20:02 UTC

TG Therapeutics shares are higher as HC Wainwright reiterates its Buy rating. Social media valuations suggest a price range of $78 to $85 per share.

1 wrz 2026, 19:54 UTC

TG Therapeutics shares are rising as H.C. Wainwright maintains a Buy rating and sets a price target of $78, indicating significant upside potential.

31 sie 2026, 22:16 UTC

TG Therapeutics Inc. shares showed little change in after-market trading. The stock remains above its 20-day moving average, indicating stability.

28 sie 2026, 19:51 UTC

TG Therapeutics Inc shares are lower today, continuing a decline since Thursday's close. The stock remains above its 20-day moving average.

27 sie 2026, 23:41 UTC

TG Therapeutics Inc shares are lower in after-market hours, reflecting broader market declines. Economic indicators have not alleviated cautious sentiment amid inflation concerns.

26 sie 2026, 19:16 UTC

TG Therapeutics raised its Briumvi revenue guidance to $890-$905 million, contributing to an upgrade of TGTX stock. Shares are trading roughly flat today.

25 sie 2026, 23:36 UTC

TG Therapeutics Inc. shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and near its one-month trading range.